Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

Urology

Volumn 46, Issue 4, 1995, Pages 477-483

  Lowe, Franklin C ^a,b,c   Mcdaniel, Ron L ^a,b,c   Chmiel, Joseph J ^a,b,c   Hillman, Alan L ^a,b,c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; TERAZOSIN;

ARTICLE; ASTHENIA; COST BENEFIT ANALYSIS; HUMAN; MALE; MODEL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYNCOPE; TRANSURETHRAL RESECTION; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DECISION TREES; ENZYME INHIBITORS; FINASTERIDE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PRAZOSIN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX;

EID: 0029552647     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80258-1     Document Type: Article

References (34)

1. Benign prostatic hyperplasia: drug and nondrug therapies
2. The costs of prostatectomy for benign prostatic hyperplasia
3. An assessment of prostatectomy for benign urinary tract obstruction. Geographic variations and the evaluation of medical care outcomes
4. Benign Prostatic Hyperplasia: Diagnosis and Treatment: Clinical Practice Guideline No. 8. Rockville, MD
5. Natural history of benign prostatic hypertrophy and acute urinary retention
6. Epidemiology and natural history of benign prostatic hyperplasia
7. Mortality and reoperation following prostatectomy: outcomes in a Medicare population
8. Clinical experience: symptomatic management of BPH with terazosin
9. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia
10. The clinical development of a 5 alphareductase inhibitor, finasteride
11. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals
12. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
13. Pharmacoeconomics and the evaluation of drugs and services
14. Vital Statistics oj the United States, 1989
15. Decision analysis
16. The American Urological Association Symptom Index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association
17. Alpha blockers in the treatment of benign prostatic hypertrophy
18. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis
19. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia
20. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia
21. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial
22. Effect of terazosin on urine storage and voiding in the aging male with prostatism
23. Watchful waiting versus immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences
24. Symptom status and quality of life following prostatectomy
25. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies
26. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia
27. Finasteride
28. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia
29. Medical Economics Data
30. Clinical economics. A guide to the economic analysis of clinical practices
31. A clinician's guide to costeffectiveness analysis
32. Benign prostatic hyperplasia: intervene or wait?
33. Benign prostatic hyperplasia: intervene or wait?
34. Benign prostatic hyperplasia: intervene or wait?